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Despite the annual public health burden of seasonal influenza and the continuing threat of a global pan-
demic posed by the emergence of highly pathogenic/pandemic strains, conventional influenza vaccines
do not provide universal protection, and exhibit suboptimal efficacy rates, even when they are well
matched to circulating strains. To address the need for a highly effective universal influenza vaccine,
we have developed a novel M2-deficient single replication vaccine virus (M2SR) that induces strong
cross-protective immunity against multiple influenza strains in mice. M2SR is able to infect cells and
expresses all viral proteins except M2, but is unable to generate progeny virus.
M2SR generated from influenza A/Puerto Rico/8/34 (H1N1) protected mice against lethal challenge
with influenza A/Puerto Rico/8/34 (H1N1, homosubtypic) and influenza A/Aichi/2/1968 (H3N2, hetero-
subtypic). The vaccine induced strong systemic and mucosal antibody responses of both IgA and IgG
classes. Strong virus-specific T cell responses were also induced. Following heterologous challenge, sig-
nificant numbers of IFN-c-producing CD8 T cells, with effector or effector/memory phenotypes and speci-
fic for conserved viral epitopes, were observed in the lungs of vaccinated mice. A substantial proportion of
the CD8 T cells expressed Granzyme B, suggesting that they were capable of killing virus-infected cells.
Thus, our data suggest that M2-deficient influenza viruses represent a promising new approach for
developing a universal influenza vaccine.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Seasonal influenza viruses cause between 3000 and 50,000
deaths and an average of 200,000 hospitalizations in the US alone,
while historically, global influenza pandemics have resulted in 50–
100 million deaths world-wide [1]. The recent emergence of highly
pathogenic avian H5N1 and H7N9 strains and the 2009 H1N1 influ-
enza pandemic emphasize the continuing threat to human health
posed by this virus. Currently approved vaccines, inactivated split
or subunit and live attenuated influenza vaccines (LAIV), must be
reformulated annually based on the influenza strains predicted to
be prevalent in the next flu season. Thus, these vaccines are not
effective if they are poorly-matched to circulating strains, as
occurred recently in the 2014/2015 flu season [2]. Although LAIV
has previously demonstrated protection in seasons with antigeni-
cally mismatched vaccines in children [3–5], accumulating data
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existing immunity present in most adults [6–8]. Thus, current vac-
cines offer little protection against antigenically distinct strains
which have the potential to cause influenza pandemics. In addi-
tion, most formats are produced by cumbersome procedures in
eggs requiring adaptation. The 2009/2010 pandemic vaccine
response underscored the urgent need for an effective universal
influenza vaccine that can be produced more quickly [9].
To address this need, we developed a novel M2 deficient influ-
enza vaccine that is able to infect cells and therefore induce strong
innate, cell mediated and humoral immunity, but does not produce
progeny virus.
The influenza A M2 protein has ion channel activity and acts at
an early stage in the virus life cycle between viral entry and
uncoating [10,11]. The M2 cytoplasmic tail also plays a role in viral
assembly and is essential for infectious virus production [12–14].
Our previous studies have demonstrated that M2 cytoplasmic tail
mutants can function as live attenuated vaccines and provide
effective protection against homologous strains [15–17]. Here we
describe a second-generation M2 knockout vaccine format
(M2SR), where we abrogated M2 expression by deletion of the
M2 transmembrane domain in addition to the insertion of two stop
codons downstream of the M1 open reading frame. In the present
study, we evaluated the ability of M2SR to induce protective
immune responses against both homologous and heterologous
influenza virus challenge.2. Materials and methods
2.1. Cells and viruses
293T human embryonic kidney cells (ATCC CRL-3216), MDCK
(Sigma-Aldrich, St. Louis, MO, USA) and M2CK (MDCK cells that
stably express the influenza M2 protein) [14] cells were main-
tained in Dulbecco’s modified Eagle’s medium supplemented with
10% FCS and in MEM containing 10% FCS, respectively, at 37 C in
5% CO2. M2CK cells were supplemented with hygromycin B
(150 lg/mL).
Influenza A PR8 and wildtype A Aichi/2/1968 (Aichi) viruses and
M2SR were grown in MDCK and M2CK cells, respectively, in the
presence of 1 lg/ml trypsin/TPCK. All viruses were stored at
80 C until usage.
2.2. M2SR virus generation
M2SR virus (a recombinant PR8 virus with a non-functional M2
protein) was generated using a plasmid rescue system described
previously [18]. Briefly, PR8 cDNA (H1N1) was synthesized as
described by Hoffmann et al. [19]. Each influenza segment was
cloned between the human RNA polymerase I promoter and the
mouse RNA polymerase I terminator as previously described [18].
The M2SR M segment was modified by introducing two stop
codons in the M2 protein ORF downstream of the M1 ORF followed
by deletion of the M2 transmembrane domain. 293T cells were
transfected as previously described [15]. M2SR virus in transfec-
tion supernatant was amplified in M2CK cells.
2.3. Mice
Six to 8 week-old female mice, 17–20 g in weight (Harlan Labo-
ratories, Livermore, CA or Madison, WI) were used in all experi-
ments. All study protocols were approved by the FluGen or BRISC
Institutional Animal Care and Use Committees and all experiments
were performed in accordance with the National Institutes of
Health guidelines for the care and use of laboratory animals.2.4. Infection and sample collection
Mice were anesthetized with either isoflurane or 2,2,2 tribro-
moethanol and were infected IN with viruses in 50 ll of sterile
PBS. Mock-infected control mice received PBS alone. Additional
groups received formalin inactivated whole PR8 virus (1 lg/-
mouse; Charles River, North Franklin, CT) either IN or IM. Six weeks
post-infection, mice were challenged IN with 100 MLD50 PR8 or 40
MLD50 Aichi. At specified intervals after immunization or chal-
lenge, groups of mice were euthanized and their lungs and nasal
turbinates were collected for determination of virus titer. Alterna-
tively, BAL and sera were collected for antibody titer and cytokine
analysis.
2.5. Virus titrations from organs
Whole lung or nasal turbinate samples from infected mice were
homogenized in 1 mL MEM containing 0.3% BSA (Thermo Fisher
Scientific, Waltham, MA). Homogenates were clarified by low
speed centrifugation and virus titers were determined on MDCK
or M2CK monolayers, as previously described [15] by plaque assay
or TCID50 assay.
2.6. Virus-specific antibody detection
Immunoglobulin IgG and IgA titers were measured in sera and
trachea-lung washes by ELISA as previously described [17] against
purified inactivated influenza PR8 antigen (Charles River, North
Franklin, CT).
A standard HAI assay was performed to assess functional anti-
body levels [20]. Serum samples were treated with RDE (Denka
Seiken, Tokyo, Japan) overnight at 37 C followed by heat inactiva-
tion for 1 h at 56 C. Twofold dilutions of RDE-treated serum sam-
ples were incubated with influenza viruses (4 hemagglutination
units per well) and 50 lL of a 0.5% suspension of turkey red blood
cells (Innovative Research, Novi, MN) for 30 min at room tempera-
ture. The HAI titer is the reciprocal of the highest dilution of RDE-
treated serum that prevented hemagglutination.
2.7. Lymphocyte subsets in the BAL
Lymphocyte or T cell subsets in the BAL were analyzed by stain-
ing with fluorochrome-conjugated antibodies to cell surface mark-
ers followed by flow cytometric analysis using a BD FACSCalibur
flow cytometer and Cellquest Pro software. Subsets of T cells were
analyzed by staining with fluorochrome-conjugated antibodies to
T cell subsets defined by the markers shown in Supplementary
Table 1. Antibodies were obtained from BD Biosciences, Biolegend
or E-Biosciences (San Diego, CA).
2.8. Restimulation of CD4 and CD8 T cells with influenza epitope
peptides
BAL cells were restimulated in vitro for 6 h with 1 lM T cell epi-
tope peptides in the presence of monensin (Golgi-Plug, BD
Biosciences, San Diego, CA). Restimulated cells were stained with
fluorochrome-conjugated anti-CD4 or anti-CD8 as described above.
Cells were then fixed and permeabilized using Cytofix/Cytoperm
reagent, stained with fluorochrome-conjugated anti-IFN-c anti-
bodies (BD Bioscience, San Diego, CA) and analyzed by flow
cytometry.
2.9. Cytokine ELISAs
Cytokine concentrations in cell free BAL fluid were determined
by sandwich ELISA as described in Sarawar and Doherty [21] with
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3.1. M2SR virus is restricted in normal cells
We modified the previously described M2 knock-out influenza
A virus [15] by deleting additional nucleotides after the two M2
protein stop codons inserted downstream of the PR8 M1 open
reading frame (Supplementary Fig. 1). The resulting M2SR virus
encodes the M2 ectodomain, but lacks the coding capacity for
the M2 transmembrane domain and cytoplasmic tail. The replica-
tion restriction and genetic stability for 20 passages of the M2SR
virus, its ability to express influenza proteins and attenuation in
mice are described in Supplementary Figs. 2–4.1.E+00
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Fig. 1. M2SR induces strong humoral and mucosal antibody responses. BALB/c mice
(21 per group), anesthetized with isoflurane, were vaccinated with M2SR (1.2  1043.2. M2SR virus elicits both systemic and mucosal immune responses
in mice
The immunogenicity of M2SR-PR8 virus in mice was compared
to that of live wild-type PR8 virus, both administered IN, or to inac-
tivated whole PR8 virus, administered either IM or IN. Three weeks
after immunization, serum and BAL were collected from the mice
and anti-PR8 IgG and IgA levels were measured by ELISA. Mice in
the immunized groups showed higher levels of anti-PR8 antibodies
in serum and BAL compared to the control group (Fig. 1). Serum
anti-PR8 IgG levels for the M2SR vaccinated group were higher
than the inactivated PR8 vaccinated groups and similar to the live
PR8 virus vaccinated group. More importantly, anti-PR8 IgA anti-
bodies were present only in the live PR8 and M2SR immunized
mice in both sera and BAL. These data demonstrate that M2SR virus
elicits systemic and mucosal immune responses in mice.PFU), live wildtype PR8 (10 PFU), inactivated PR8 (1 lg) or vehicle (PBS) intranasally
(IN) or inactivated PR8 (1 lg) intramuscularly (IM). Three weeks after vaccination,
serum and bronchoalveolar lavage (BAL) were collected from mice (N = 5). For BAL
collection, mice were anesthetized with isoflurane and exsanguinated via the
femoral artery. The trachea was cannulated via a small incision and two lavages
were performed with a total volume of 1 ml PBS. BAL was harvested after low speed
centrifugation to pellet cells. Anti-PR8 IgG and IgA levels were measured by ELISA
for pooled sera for each group. 96 well high protein–binding plates (Nunc MaxiSorp,
Thermo Fisher Scientific, Waltham, MA) were coated with 200 ng/well purified
inactivated influenza PR8 antigen (Charles River Avian Vaccine Services, North
Franklin, CT). After incubation of the plates with test samples, bound antibody was
detected using horseradish peroxidase-conjugated goat anti-mouse IgG or goat
anti-mouse IgA followed by development with SureBlue TMB Microwell Peroxidase
Substrate (KPL, Gaithersburg, MD). Endpoint antibody titers are given as the
reciprocal of the dilution determined by least squares method giving an OD reading
of 0.3 at 450 nM and three standard deviations above the mean background. Panel
A. Antibody titers in sera. Panel B. Antibody titers in BAL.3.3. M2SR virus protects mice from lethal homosubtypic and
heterosubtypic challenge
The protective efficacy of M2SR virus was evaluated by chal-
lenging groups of mice, immunized as described above, with lethal
doses of the wild-type PR8 (H1N1; homosubtypic challenge) or
Aichi (H3N2; heterosubtypic challenge) six weeks post-
immunization. None of the mice immunized with either M2SR or
live wild-type PR8 and subsequently challenged by wild-type
PR8 showed any clinical symptoms, including weight loss
(Fig. 2A & B). In contrast, control mice lost more than 20% of their
body weight and died or were euthanized due to severe illness by
day 5 (Fig. 2A & B). No virus was detected in the lungs or nasal tur-
binates of M2SR or live PR8 immunized mice, 3 days after homo-
subtypic challenge (Fig. 3A), indicating that M2SR induced
sterilizing immunity similar to wild-type PR8 infection. In contrast,
challenge PR8 virus was recovered from the lungs of the inacti-
vated PR8-immunized and control groups.
All M2SR-immunized mice survived the heterosubtypic chal-
lenge with Aichi virus, as did mice immunized with wild-type
PR8 (Fig. 2C & D). Mice in both groups displayed 10–15% weight
loss but recovered fully. In contrast, mice that had received inacti-
vated PR8, or PBS alone, continued to lose weight and succumbed
to infection (Fig. 2C & D). Although M2SR vaccinated mice recov-
ered from heterosubtypic challenge, virus was detected in the
lungs and nasal turbinates at day 3 after challenge (Fig. 3B), indi-
cating that heterosubtypic sterilizing immunity was not elicited.Serum collected from all challenge survivors was evaluated for
HAI titers against both PR8 and Aichi challenge viruses. All vacci-
nated mice survived and had high HAI titers to PR8, fourteen days
after homologous challenge with a lethal dose of the virus (Fig. 3C),
which likely reflected responses induced by the vaccines that were
boosted on subsequent homologous challenge. The fact that the
Aichi-challenged mice that survived had much lower HAI titers
to PR8 at the same time-point supports this idea. HAI titers to Aichi
(heterologous challenge) were much lower for M2SR-PR8 and PR8
vaccinated mice (Fig. 3C). As all of these mice survived, it is prob-
able that other mechanisms, for example anti-viral T cell
responses, contributed to heterologous protection. Only 1 out of
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Fig. 2. M2SR protects against homologous and heterologous challenge. Mice (remaining 16 of 21) that were vaccinated as described in the legend to Fig. 1 were challenged
6 weeks later (N = 8 per virus) with a lethal dose of homologous virus (PR8, H1N1); (A & B) or heterologous virus (Aichi, H3N2); (C & D). Weight loss (A & C) and survival (B &
D) were monitored for 14 days for 5 mice per challenge virus. Differences in the survival curves were statistically significant: *P = 0.002. The survival analysis was performed
using the Log-rank test (Mantel-Cox method) in Graphpad Prism software. P-value less than 0.05 is considered significant.
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this mouse had an HAI titer of 40 (Fig. 3C), which may not be rep-
resentative of the group as a whole, as most did not survive chal-
lenge, but probably explains the survival of this individual.3.4. M2SR elicits influenza-specific T cell responses that are recalled
upon heterologous challenge
As an initial step in evaluating the possibility that T cell
responses may mediate heterosubtypic protection, influenza speci-
fic responses were evaluated and compared to responses induced
by a sub-lethal dose of PR8. Mice vaccinated with M2SR or wild-
type virus had similar total numbers of cells and similar propor-
tions of ab TCR+ve cells in the BAL at days 4 and 7 after challenge
(Supplementary Fig. 5). The relative proportions of CD4 and CD8 T
cells were similar at day 4 after challenge, whereas for both M2SR
and wild-type virus vaccinated groups, CD8 T cells predominated
by day 7 after challenge (Supplementary Fig. 5). Both groups had
significant populations of NK cells in the BAL at day 4 after chal-
lenge, although this cell type had dispersed by day 7. Very few
CD19+ B cells or cd TCR+ve cells were observed (Supplementary
Fig. 5).
In contrast to mice vaccinated with M2SR or live virus, unvacci-
nated mice had very few CD8 or CD4 T cells in the BAL at day 4
(Fig. 4) confirming that the observed responses in mice vaccinated
with M2SR or live virus were not primary, but recalled secondary
responses. BAL cells from mice vaccinated with M2SR or wild-
type virus were restimulated in vitro with CD8 epitope peptides
NP366-374 or PB1703-711 or CD4 epitope peptides HA211-225 or
NP311-325 and stained for CD4 or CD8 and IFN-c. M2SR elicited
peptide-specific responses to similar levels as the wild-type PR8virus. These data show that M2SR vaccine elicits T cell responses
to conserved viral epitopes that are recalled upon heterologous
challenge.3.5. M2SR induces T cells with effector and effector memory
phenotypes and cytotoxic potential
T cells from the BAL of M2SR or wild-type virus vaccinated mice
were also stained with antibodies to the markers that delineate
naïve, effector, central memory, effector memory, effector memory
precursor and terminal effector subsets (Supplementary Table 1).
For both M2SR and wild-type virus vaccinated groups, the majority
of the CD8 T cells after challenge were effector or effector memory
cells with lower numbers of effector memory precursor cells
(Fig. 5A). A similar profile was observed for CD4 T cells from both
M2SR and wild type virus vaccinated mice. These data also suggest
that M2SR vaccine induces T cell responses that are recalled upon
heterologous challenge.
In order to evaluate their potential to kill virus-infected cells
after challenge, T cells from the BAL of wild-type or M2SR vacci-
nated mice were stained with antibodies to cytotoxic effector
molecules, Granzyme B or Fas ligand. A significant proportion of
CD8 T cells from both wild-type and M2SR vaccinated mice
expressed Granzyme B, although very few CD4 T cells expressed
this molecule (Fig. 5B). In contrast, a higher proportion of CD4 T
cells than CD8 T cells expressed FasL for both M2SR and wild-
type virus vaccinated mice (Fig. 5B). However, the number of
CD4 T cells present in the BAL was much lower than that of CD8
T cells. These data show that the T cells that are induced by
M2SR are armed with cytotoxic mediators and capable of killing
virus-infected cells.
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Fig. 3. M2SR induces sterilizing immunity to homologous, but not to heterologous, virus challenge. Mouse respiratory organs (lungs and nasal turbinates) were harvested on
day 3 after infection frommice (6 of 16 that were challenged; N = 3 per virus) challenged as described in the legend to Fig. 2. In brief, lung lobes were separated from the heart
and trachea while the nasal turbinates were harvested after first removing the skin from the mouse skull followed by removal of the skull to expose the intact nasal
epithelium. Lung and nasal turbinates were homogenized in MEM containing 0.3% BSA using a mortar and pestle after tissue weights were determined. Supernatants were
collected for titration after slow speed centrifugation. Virus titers were determined by TCID50 or plaque assay in MDCK cells. Homologous challenge virus titers are shown in
panel A and heterologous challenge virus titers are shown in panel B (mean ± SD). The limit of detection (LOD) for the plaque assay is 10 PFU/organ and 101.67 TCID50/organ for
the TCID50 using the Reed-Muench method of determining the 50% infectious endpoint. Panel C. Serum samples were obtained from surviving mice 14 days after challenge
and HAI titers were determined on pooled samples from groups of 5 mice using turkey erythrocytes. N.D. not determined since all mice died. *Titer for surviving mouse only
and may not be representative of group as 80% of the mice died.
5094 S. Sarawar et al. / Vaccine 34 (2016) 5090–50983.6. Moderate inflammatory responses are observed in M2SR
vaccinated mice after challenge
We examined the cell types and cytokines induced after hetero-
subtypic challenge in M2SR or wild-type virus vaccinated groups of
mice. At day 4 after challenge, M2SR vaccinated mice had a signif-
icantly lower proportion of neutrophils and a significantly higher
proportion of lymphocytes in the BAL than unvaccinated mice
(Fig. 6A). Wild-type virus vaccinated mice showed intermediate
percentages of lymphocytes and neutrophils. The percentage of
macrophages in all three groups was similar. However, by day 7
after challenge, similar percentages of macrophages, lymphocytes
and neutrophils were found in the BAL of M2SR and wild-type
virus-vaccinated mice (Fig. 6B). Extremely low numbers of eosino-
phils and no basophils or mast cells were observed in the BAL of all
three groups of mice at both days 4 and 7 after challenge
(Fig. 6A & B).
Cytokine levels were determined in cell-free BAL fluid. Very low
levels of IL-2, IL-4, IL-17 and IL-10 were detected in the BAL of
M2SR or live virus vaccinated mice or unvaccinated controls after
challenge (Fig. 6C). Moderate levels of IFN-c and TNF were
detected in the BAL of all 3 groups of mice after challenge (Fig. 6C).
Levels of IFN-c and TNF in the BAL of the M2SR and wild-type virusvaccinated groups were similar at day 7 after challenge and some-
what higher than at day 0 or day 4 for both groups.
4. Discussion
Our data show that M2SR provides effective protection against
both homologous and heterologous strains of influenza. These
promising results suggest that M2SR could offer a major advantage
over currently approved vaccines, which offer little or no protec-
tion against newly emerging or mutated strains [22,23]. Whereas
LAIV has provided protection in children in seasons in which the
antigenicity of the virus has drifted [3–5,24], recent studies suggest
that LAIV may not be as effective in adults due to preexisting
immunity [9,25]. M2SR can be produced efficiently in cell culture,
avoiding the many disadvantages of production in eggs. The vac-
cine can be rapidly engineered to match new pandemic strains,
without the need for adaptation to growth in eggs. Data from mul-
tiple passage studies shows that the vaccine is genetically stable
and does not re-acquire the ability to produce M2 or to replicate
in cells, other than the M2-expressing producer line.
M2SR induces sterilizing immunity to homosubtypic challenge
(Fig. 2). This is likely to be mediated by neutralizing antibodies
to the head region of the hemagglutinin molecule, since the
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Fig. 4. M2SR induces T cell responses to conserved viral epitopes. C57BL/6 mice were vaccinated IN with either M2SR (106 PFU) or a sublethal dose of PR8 (30 PFU). Mice were
challenged 5 weeks later with a lethal dose of Aichi (40 MLD50 IN.). For BAL collection, mice were anesthetized with a lethal dose of tribromoethanol and exsanguinated via
the axillary vein. The trachea was cannulated via a small incision and three lavages were performed with a total volume of 1 ml PBS. The BAL cellular component was
collected by low speed centrifugation. Viable cell (total leukocyte) counts were performed by Trypan Blue exclusion. BAL cells harvested 4 and 7 days after challenge were
restimulated in vitro with 1 lM T cell epitope peptides for 6 h in the presence of monensin. BAL was also harvested from additional groups of mice that were vaccinated but
not challenged (designated ‘Day 0’) and challenged but not vaccinated (‘unvaccinated’). BAL was harvested from the latter group at day 4 only. Cells were stained with FITC-
conjugated anti-CD4 (RM4-5) or anti-CD8 (53-6-7), fixed, permeabilized and stained with PE-conjugated anti-IFN-c (XMG1.2) antibody and analyzed by flow cytometry.
Dead cells, erythrocytes, small vesicles and debris were excluded using forward and side scatter gates. The absolute cell number in each lymphocyte subset was calculated by
multiplying the fraction of leukocytes that were positive for markers of that subset by the total number of leukocytes. The mean percentages of CD8 T cells that produced IFN-
c in response to the NP366 peptide were 16.6% and 27.3% for M2SR-vaccinated and WT virus- vaccinated groups, respectively. The corresponding percentages for the PB1 703
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number per mouse. C. Total BAL CD4+ cell number per mouse. D. Number of CD8+ cells producing IFN-c in response to restimulation with NP366-374 peptide. E. Number of CD8+
T cells producing IFN-c in response to PB1703-711 peptide. F Number of CD4+ T cells producing IFN-c in response to HA211-225 peptide. G Number of CD4+ T cells producing IFN-
c in response to NP311-325 peptide. Data shown are means + SEM for 3 groups of 3–5 mice/group. *, significantly different from day 0 timepoint (*P < 0.05, **P < 0.01,
***P < 0.001). #, significantly different from unvaccinated group (P < 0.05). Statistical analysis was performed using Student’s t test and Graphpad Prism software (Graphpad
Software, La Jolla, CA).
S. Sarawar et al. / Vaccine 34 (2016) 5090–5098 5095vaccine induces high HAI titers that are boosted on homologous
challenge (Fig. 3C). In contrast, immunity to heterosubtypic
challenge was not sterilizing. Protective HAI titers against the chal-
lenge virus were not elicited suggesting that protection is unlikely
to be mediated by neutralizing antibodies to the hemagglutinin.
The mouse model is routinely used in the preclinical evaluation
of influenza vaccine candidates [26–32]. It remains to be seen
how these promising results with M2SR will translate to humans.
Studies in the literature on heterosubtypic immunity to live
virus have given divergent results, implicating both humoral and
cell-mediated mechanisms of protection [27,33–36]. M2SR induces
strong systemic and mucosal antibody responses. It is possible that
heterosubtypic protection is mediated by cross-reactive non-neutralizing antibodies to HA2 (stalk) region of the hemagglutinin
molecule, which is more conserved than the head region, or to con-
served epitopes in the neuraminidase molecule. Non-neutralizing
antibodies might control virus by mechanisms such as antibody-
dependent cellular cytotoxicity (ADCC).
Alternatively, protection may be mediated by cross-reactive T
cells responding to epitopes shared between the vaccine and chal-
lenge viruses. Most of these shared epitopes are in conserved intra-
cellular proteins, such as the nucleoprotein and polymerase. M2SR
induces an influenza specific T cell response that is recalled upon
heterologous challenge and is similar to that induced by a sub-
lethal dose of live wildtype virus. Large numbers of CD8 T cells,
and lower numbers of CD4 T cells producing IFN-c in response to
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5096 S. Sarawar et al. / Vaccine 34 (2016) 5090–5098conserved viral epitopes were observed in the BAL of M2SR-
vaccinated mice after heterologous challenge. The majority of both
CD4 and CD8 T cells had effector or effector memory phenotypes,
with lower numbers of effector memory precursors. In a recent
study on cellular immune correlates of protection against the
2009 H1N1 influenza in humans, Sridhar et al. [37] reported that,
in the absence of cross-reactive neutralizing antibody, the fre-
quency of CD8 T cells specific to conserved viral epitopes corre-
lated with cross-protection against symptomatic influenza. In the
latter study, low symptom scores were significantly associated
with the presence of IFN-c-producing CD8 T cells with effector
memory phenotype responding to conserved epitopes in NP and
PB-1 viral proteins. This is the same phenotype that we observe
in M2SR-vaccinated mice, following heterosubtypic challenge.
Furthermore, our data shows that a substantial proportion of
the CD8 T cells in the BAL of M2SR vaccinated mice express the
cytotoxic mediator, Granzyme B, after heterosubtypic challenge.
In addition, some CD4 T cells in the BAL expressed FasL, although
they were present in much lower numbers than the CD8 T cells
expressing Granzyme B. Thus, the T cells in the BAL were armed
with cytotoxic mediators, suggesting that they were capable of
killing virus-infected cells. Influenza-specific CD4 T cells that pre-
sented cytotoxic characteristics were shown to correlate with
reduced influenza disease in a human challenge model [38]. High
levels of Granzyme B and high IFN-c/IL10 ratios (which we also
observed) have been shown to correlate with protection against
influenza in vaccinated older individuals [39,40].
Some vaccines to respiratory viruses have been associated with
the induction of dysfunctional immune responses upon natural
exposure to virus. For example, an early respiratory syncytial virus
(RSV) vaccine induced eosinophilia and asthma–like responses in
children following community-acquired infection with RSV [41].
In addition, some, but not all, reports have described wheezing in
children vaccinated with LAIV (FluMist) [42–44] and enhancementof influenza virus respiratory disease by vaccine induced anti-HA2
antibodies has been reported in pigs [45]. Although M2SR induced
sterilizing immunity to homosubtypic challenge, viral replication
in the lungs was observed after heterosubtypic challenge and could
potentially have induced a dysfunctional inflammatory response in
vaccinated mice. Therefore, we examined the cellular infiltrate in
the lungs after heterosubtypic challenge in mice vaccinated with
M2SR. We observed a moderate cellular infiltrate comprising
mainly lymphocytes and macrophages with lower numbers of neu-
trophils. Very few eosinophils, basophils or mast cells, cell types
that are associated with bronchial hyperresponsiveness, wheezing
and asthma, were observed.
In general, cytokine concentrations induced by M2SR were low
and only moderate levels of IFN-c and TNF were observed in the
BAL, with virtually no IL-2, IL-10 or IL-17. This is not consistent
with the extremely high levels of cytokines (the so-called ‘cy-
tokine storm’) that are observed during severe or lethal influenza
infection and have been postulated to play a role in lung damage
[20]. Taken together these data suggest that M2SR induces effec-
tive protection without inducing damaging inflammatory
responses.
In summary, our data show that M2SR vaccine is a genetically
stable vaccine, with the advantage that it can be produced rapidly
in cell culture, avoiding the pitfalls of vaccine production in eggs.
The vaccine induces strong humoral and cellular immunity that
provides effective homosubtypic and heterosubtypic protection
in a mouse model and induces known correlates of immune pro-
tection in humans.Conflict of interest statements
S.S., P.D. and S.W. have no conflicts of interest. G.N. and Y.K. are
founders of FluGen. Y.H. and P.B. are employees of FluGen.
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